文献速递介入腹部CTDSA

不可切除早期肝细胞癌且术中出血高风险患者的介入肿瘤治疗:单步联合治疗是否安全可行

Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible?
PubMed 文献 · Eur J Radiol · 2019-02-23

这项前瞻性单中心观察性研究纳入143例肝硬化合并单发肝细胞癌(<8 cm)患者,按凝血功能分为低、中、高风险三组,评估射频消融联合经动脉化疗栓塞(RFA+TACE)单步联合治疗的技术成功率、围手术期并发症及实验室指标变化;C组1个月完全缓解率与既往仅行TACE的16例匹配对照患者比较显著更高(p < .001)。

要点

  • 所有患者单步RFA+TACE均获技术成功,无重大并发症。
  • C组(高风险)RFA后轻微并发症率显著更高,但后续TACE成功处理。
  • C组1个月完全缓解率与对照TACE组比较显著更高(p < .001)。

核心结论

  • 单步RFA联合TACE治疗可扩大经皮热消融的适应证,使既往因出血相关操作高风险并发症而禁忌的病例也可纳入,从而改善短期患者结局。

研究设计与样本

  • 前瞻性单中心观察性研究,2010年1月至2017年6月连续纳入143例肝硬化合并单发肝细胞癌(<8 cm)患者,按凝血试验分为A组(低风险)、B组(中风险)、C组(高风险);对照为既往由同一操作者仅行TACE的16例匹配严重凝血病患者。

诊断标准与关键数值

  • 技术成功率:所有患者均获技术成功,无重大并发症。
  • C组RFA后轻微并发症率显著高于其他组,但患者经后续TACE治疗成功,术前与术后实验室值无差异。
  • 1个月完全缓解率:三组相似;C组显著高于对照TACE组(p < .001)。

临床应用与阅片要点

  • 作者认为单步RFA联合TACE可扩大经皮热消融适应证,使既往因出血相关操作高风险并发症而禁忌的病例也可纳入。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study was designed to assess the feasibility and safety of a single-step combined therapy using radiofrequency ablation and transarterial chemoembolization (RFA + TACE) in patients with hepatocellular carcinoma (HCC) and uncontrolled coagulopathy. The study also aimed to compare the effectiveness of this approach with TACE alone, performed in a control group.

MATERIAL AND METHODS: One hundred and forty-three consecutive cirrhotic patients having a single HCC < 8 cm were enrolled in this observational prospective single-center study from January 2010 to June 2017 and were divided, according to coagulation tests, into three groups (A: low risk; B: intermediate risk and C: high risk of bleeding). The feasibility and safety of a single-step combined treatment (RFA followed by TACE) were evaluated in terms of technical success rate, periprocedural complications, and laboratory values variations. Tumor response obtained at 1-month CT follow-up for group C was compared with that of control group, composed by 16 matched patients with severe coagulopathy and single HCC < 8 cm, who underwent only TACE in a previous period, performed by the same operator.

RESULTS: Technical success was achieved in all patients, without any major complications. Minor complications rate was significantly higher in group C after RFA; however, the patients were successfully treated with subsequent TACE therapy, without any differences between pre- and post-procedural laboratory values. One-month complete response rates were similar in all the three groups; however, the response rates of group C were significantly higher as compared to that of the control TACE Group (p < .001).

CONCLUSION: The single-step RFA plus TACE therapy allows expansion of the indication for percutaneous thermal ablation, allowing to also include cases previously contraindicated due to the procedural high-risk of complications associated with bleeding, thus improving short-term patient outcome.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Iezzi R, Pompili M, Posa A, et al. Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? Eur J Radiol. 2019. PMID: 31005173. doi:10.1016/j.ejrad.2019.02.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。